Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA combined with erythropoietin and iron for hidden blood loss in elderly hip fracture
ChiCTR2000031125Phase 4Not yet recruiting
- Sponsor
- Chongqing General Hospital
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tranexamic acid, erythropoietin and Iron in hip fracture (4 arms), sponsored by Chongqing General Hospital. Primary endpoints: Hemoglobin, Hematocrit and 4 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
tranexamic aciderythropoietinIron
03
Conditions
hip fracture
Beyond the preview
Go deeper on ChiCTR2000031125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031125.